Details for New Drug Application (NDA): 022003

« Back to Dashboard

NDA 022003 describes NOXAFIL, which is a drug marketed by Merck Sharp Dohme and Schering and is included in three NDAs. It is available from one supplier. There are nine patents protecting this drug and three Paragraph IV challenges. Additional details are available on the NOXAFIL profile page.

The generic ingredient in NOXAFIL is posaconazole. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the posaconazole profile page.

Summary for 022003

Tradename:	NOXAFIL
Applicant:	Schering
Ingredient:	posaconazole
Patents:	3
Formulation / Manufacturing:	see details

Generic Entry Opportunity Date for 022003

Generic Entry Date for 022003^: ➤ Try a Free Trial* Constraining patent/regulatory exclusivity: ➤ Try a Free Trial Dosage: SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022003

Suppliers and Packaging for NDA: 022003

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NOXAFIL	posaconazole	SUSPENSION;ORAL	022003	NDA	Merck Sharp & Dohme Corp.	0085-1328	0085-1328-01	1 BOTTLE, GLASS in 1 CARTON (0085-1328-01) > 105 mL in 1 BOTTLE, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SUSPENSION;ORAL			Strength	40MG/ML
Approval Date:	Sep 15, 2006	TE:		RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	Jul 19, 2019	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
Patent:	➤ Try a Free Trial	Patent Expiration:	Oct 5, 2018	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
Patent:	➤ Try a Free Trial	Patent Expiration:	Apr 1, 2022	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 022003

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	➤ Try a Free Trial	➤ Try a Free Trial
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.